...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells
【24h】

Activation of p53/miR-34a Tumor Suppressor Axis by Chinese Herbal Formula JP-1 in A549 Lung Adenocarcinoma Cells

机译:中草原型JP-1在A549肺腺癌细胞中的P53 / miR-34A肿瘤抑制轴的激活

获取原文
获取原文并翻译 | 示例
           

摘要

Lung cancer is the leading cause of cancer death worldwide; the most common pathologic type is lung adenocarcinoma (LADC). In spite of the recent progress in targeted therapy, most LADC patients eventually expired due to the inevitable recurrence and drug resistance. New complementary agent with evidence-based molecular mechanism is urgently needed. MiR-34a is an important p53 downstream tumor suppressor, which regulates apoptosis, cell-cycle, EMT (epithelial mesenchymal transition), and so forth. Its expression is deficient in many types of cancers including LADC. Here, we show that a Chinese herbal formula JP-1 activates p53/miR-34a axis in A549 human LADC cells (p53 wild-type). Treatment with JP-1 induces p53 and its downstream p21 and BAX proteins as well as the miR-34a, resulting in growth inhibition, colony formation reduction, migration repression, and apoptosis induction. Accordingly, the decreases of miR-34a downstream targets such as CDK6, SIRT1, c-Myc, survivin, Snail, and AXL were observed. Moreover, JP-1 activates AMPKalpha and reduces mTOR activity, implying its inhibitory effect on the energy-sensitive protein synthesis and cell proliferation signaling. Our results show that JP-1 activates p53/miR-34a tumor suppressor axis and decreases proteins related to proliferation, apoptosis resistance, and metastasis, suggesting its potential as a complementary medicine for LADC treatment.
机译:肺癌是全世界癌症死亡的主要原因;最常见的病理型是肺腺癌(LADC)。尽管有针对性治疗的最近进展,但大多数LADC患者由于不可避免的复发和耐药性而最终到期。迫切需要具有循证分子机制的新补充剂。 miR-34a是一个重要的p53下游肿瘤抑制因素,其调节细胞凋亡,细胞周期,EMT(上皮间充质转换)等。其表达缺乏许多类型的癌症,包括LADC。在这里,我们表明中草原JP-1在A549人Ladc电池(P53野生型)中激活P53 / miR-34A轴。用JP-1治疗诱导P53及其下游P21和Bax蛋白以及miR-34a,导致生长抑制,菌落形成还原,迁移抑制和凋亡诱导。因此,观察到MiR-34A下游靶标如CDK6,SIRT1,C-MYC,Survivin,蜗牛和AXL的降低。此外,JP-1激活AMPKαba并减少MTOR活性,暗示其对能量敏感蛋白质合成和细胞增殖信号传导的抑制作用。我们的结果表明,JP-1激活P53 / miR-34A肿瘤抑制轴,降低与增殖,凋亡抗性和转移相关的蛋白质,表明其作为LADC治疗的互补药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号